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Novel stable dendrimersome formulation for safe
bioimaging applications†
M. Filippi,a D. Patrucco,a J. Martinelli,b M. Botta,b P. Castro-Hartmann,c L. Tei*b and
E. Terreno*a
Dendrimersomes are nanosized vesicles constituted by amphiphilic Janus dendrimers (JDs), which have
been recently proposed as innovative nanocarriers for biomedical applications. Recently, we have demon-
strated that dendrimersomes self-assembled from (3,5)12G1-PE-BMPA-G2-(OH)8 dendrimers can be suc-
cessfully loaded with hydrophilic and amphiphilic imaging contrast agents. Here, we present two newly
synthesized low generation isomeric JDs: JDG0G1(3,5) and JDG0G1(3,4). Though less branched than the
above-cited dendrimers, they retain the ability to form self-assembled, almost monodisperse vesicular
nanoparticles. This contribution reports on the characterization of such nanovesicles loaded with the
clinically approved MRI probe Gadoteridol and the comparison with the related nanoparticles assembled
from more branched dendrimers. Special emphasis was given to the in vitro stability test of the systems in
biologically relevant media, complemented by preliminary in vivo data about blood circulation lifetime
collected from healthy mice. The results point to very promising safety and stability profiles of the nano-
vesicles, in particular for those made of JDG0G1(3,5), whose spontaneous self-organization in water gives
rise to a homogeneous suspension. Importantly, the blood lifetimes of these systems are comparable to
those of standard liposomes. By virtue of the reported results, the herein presented nanovesicles augur
well for future use in a variety of biomedical applications.
1. Introduction
The biomimetic materials capable of reproducing the architec-
ture and the properties of natural membranes are attracting
much interest in the field of biomedical sciences.1,2 Some
natural or synthetic amphiphiles can simulate the behaviour
of cell membrane components by self-assembling into orga-
nized structures when placed in aqueous environments.3,4
Liposomes are the best-known example of artificial nanosized
vesicles, and consist of a phospholipid bilayer entrapping an
aqueous core.5,6 They are successfully used for a number of
biomedical purposes: from model systems to study biological
membranes to efficient vectoring carriers for delivering bio-
active substances or other molecules to pathological sites.7–9
The need for systematic approaches to optimize specific mem-
brane physico-chemical characteristics (e.g. mechanical resist-
ance, wall thickness, chemical groups exposed on the outer
surface) has driven the search for new categories of amphi-
philes other than phospholipids.10–12 Two examples are rep-
resented by polymersomes13–15 and dendrimersomes,16–22
which are obtained through the self-assembly of amphiphilic
block co-polymers or JDs, respectively. Whereas the potential
of polymersomes in biomedical studies has been already
demonstrated,14,15 dendrimersomes have been proposed only
very recently, and therefore their behaviour in biological
environments is largely unexplored. A relevant exception is
glycodendrimersomes, which were primarily proposed as
nanotools to investigate specific protein functionalities (e.g.
lectins), as well as the binding to biomolecules from plants
and bacteria.23–25
We have recently reported that dendrimersomes assembled
from the (3,5)12G1-PE-BMPA-G2-(OH)8 Janus dendrimer
(herein coded as JDG1G2(3,5), Fig. 1) can be loaded with both
fluorescent and magnetic resonance imaging (MRI) contrast
agents, thus potentially acting as a novel nanosized platform
for molecular imaging applications.26 Intriguingly, the encap-
sulation of the clinically approved MRI agent Gadoteridol
(Fig. 1) in the aqueous core of the dendrimersomes proved the
high water permeability of their membrane with respect to
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clinically used liposomes.27 Hence, the longitudinal relaxivity
(r1) of the paramagnetic agents encapsulated in the dendri-
mersomes (a measure of the ability to generate MRI contrast)
is not severely limited by this parameter. Thanks to these dis-
tinctive features, JDG1G2(3,5)-based dendrimersomes possess
a good diagnostic and theranostic potential.
In this contribution, two novel low-generation isomeric JDs
(coded JDG0G1(3,4) and JDG0G1(3,5)) bearing only one hydro-
phobic and one hydrophilic dendron linked together by an
ethylene glycol residue (Fig. 1) have been synthesized. The
ability of such dendrimers to form nanovesicles and to entrap
Gadoteridol was assessed and compared with the results
obtained with the higher generation dendrimersomes based
on JDG1G2(3,4) and JDG1G2(3,5). For in vivo applications, the
dendrimersomes were formulated with a small percentage of
DSPE-PEG2000-COOH to increase stability and blood residence
lifetime. For the first time, the structural integrity of this class
of nanoparticles was tested in media mimicking the physico-
chemical conditions of biological environments. Specifically,
considerable effort was made to define the stability of vesicles
in the presence of plasma components. In order to evaluate
unexpected harmful effects on cell viability and proliferation,
dendrimersomes were incubated in the presence of two dis-
tinct lines of murine macrophage (J774.A1 and RAW 264.7)
and one murine fibroblast (NIH/3T3) cell lines. Finally, the
vesicles were injected into healthy mice with the aim of asses-
sing their blood circulation lifetime.
2. Results
2.1 Synthesis of JDs and their self-assembled
dendrimersomes
The novel amphiphiles JDG0G1(3,5) and JDG0G1(3,4) were
properly designed to reduce the time required for the syn-
thesis, and with the expectations to keep unaltered, or even
improve, the physico-chemical properties of the resulting
nanovesicles. Very recently, Percec and co-workers have
reported a similar approach.18 They called these molecules
“single–single” amphiphilic Janus dendrimers, in contrast to
the “twin–twin” homologous ones previously studied.16 Such
“single–single” JDs were obtained by using short mono/bis-
amide or ester linkers connecting the hydrophilic and the
hydrophobic moieties of the molecule. Our approach was
somehow simpler, as we employed the same synthons used for
the synthesis of low generation Janus dendrimer precursors of
JDG1G2(3,5) and JDG1G2(3,4) that were connected through an
ethylene glycol linker. In particular, as reported in Scheme 1,
2-hydroxyethyl 3,5-(didodecyloxy)benzoate (1) was obtained by
reacting 3,5-(didodecyloxy)benzoic acid with an excess of ethy-
lene glycol in the presence of 4-(dimethylamino)pyridinium
p-toluenesulfonate (DPTS) and dicyclohexylcarbodiimide
(DCC). Following the same coupling procedure, 2,2,5-tri-
methyl-1,3-dioxane-5-carboxylic acid was reacted with the free
hydroxyl group of 1. Deprotection of the acetonide was carried
out in a 1 : 1 mixture of 6 M HCl and THF to obtain the gen-
eration zero intermediate 2. The final compound JDG0G1(3,5)
was obtained by repeating once again the coupling and the de-
protection steps. The preparation of the analogous compound
JDG0G1(3,4) was achieved starting from 3,4-(didodecyloxy)-
benzoic acid and following the same synthetic route (see ESI†).
Dendrimersomes composed of the synthesized JDs (with
5% addition of DSPE-PEG2000-COOH) were prepared by using
the conventional film hydration method. After extrusion and
exhaustive dialysis, spherical vesicular structures with uni-
lamellar membranes and homogeneous particle size distri-
butions were obtained, as shown by cryo-transmission electron
microscopy (Cryo-TEM) on selected systems (Fig. 2) and
Dynamic Light Scattering (DLS, Table 1). As previously
reported,16,17,20 the position of the aliphatic chains inside the
Fig. 1 Chemical structures of Gadoteridol (in the centre) and of the Janus dendrimers investigated in this work: JDG1G2(3,5) (top left), JDG1G2(3,4)
(top right), JDG0G1(3,5) (bottom left), JDG0G1(3,4) (bottom right).
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branching pattern of the amphiphilic molecules may affect the
membrane packing (Table 1 and Fig. S1†). As a consequence,
the mean hydrodynamic diameter of vesicles made of 3,5-
based JDs was found to be slightly larger than that of the
3,4-based dendrimersomes. This finding agrees with previous
studies reporting that the 3,5-positions can induce highly
interdigitated wall architectures, resulting in larger
vesicles.16,17,20
2.2 Relaxivity of dendrimersomes loaded with Gadoteridol
The normalized longitudinal proton relaxivity value r1
(20 MHz, 25 °C) of the MRI contrast agent Gadoteridol encap-
sulated in the G0G1-based dendrimersomes was only slightly
lower (Table 1) than the value measured for the non-entrapped
(“free”) complex (4.6 mM−1 s−1).26 This result confirms that
the membranes of these new dendrimersomes maintain a
high water permeability, thus preventing the decrease of r1
typically observed for the clinical-like formulations of
liposomes.27
2.3 Dendrimersome stability in vitro
The stability of the dendrimersomes was evaluated in terms of
the release of the entrapped Gadoteridol after exhaustive dialy-
sis, which was quantified by relaxometry. Stability tests were
performed in: (i) isotonic buffer at both 4 and 37 °C; (ii)
human serum (HS) at 37 °C; (iii) human serum albumin (HSA)
at 37 °C. After incubation for 1 h in isotonic buffer at 4 or
37 °C, followed by exhaustive dialysis, JDG0G1(3,4)-based den-
drimersomes released most of their cargo, thus indicating
some deficits in the basic stability or in the self-assembling
process (Fig. S2 and S3, ESI†). The release of Gadoteridol from
JDG0G1(3,4)-based vesicles was higher than from the dendri-
mersomes assembled from the other three JDs, even before
dialysis.
This result suggests that the leakage of the MRI agents
could have already started during the dialysis process that is
included in the preparation protocol of the nanovesicles.
When incubated with HS at 37 °C, dendrimersomes composed
of JDG1G2(3,4) also failed to retain their content (Fig. 3).
Scheme 1 Synthesis of JDG0G1(3,5) Janus dendrimer. i: ethylene glycol, DCC, DPTS; ii: 2,2,5-trimethyl-1,3-dioxane-5-carboxylic acid, DCC, DPTS;
iii: THF, 6 M HCl. The synthetic procedure is analogous for JDG0G1(3,4), starting from 3,4-(didodecyloxy)benzoic acid.
Fig. 2 Cryo-TEM images of JDG0G1(3,5)-based and JDG1G2(3,5)-
based dendrimersomes (top and bottom, respectively), at different mag-
nifications (25 000×, 30 000×, 40 000×), showing unilamellar vesicular
architectures with homogeneous size distribution.
Table 1 Physico-chemical properties of the investigated dendri-
mersomes
Mean
diameter [nm] PDIa
r1
b
[s−1 mM−1]
Pw
c
[μm s−1]
JDG1G2(3,5) 173.7 ± 15.9 0.15 ± 0.02 3.5 ± 0.2 146.5 ± 26.5
JDG1G2(3,4) 129.3 ± 5.2 0.20 ± 0.04 3.2 ± 0.2 170.3 ± 23.3
JDG0G1(3,5) 148.8 ± 6.4 0.13 ± 0.03 3.7 ± 0.2 139.4 ± 27.0
JDG0G1(3,4) 117.2 ± 9.9 0.18 ± 0.07 3.7 ± 0.1 148.9 ± 35.5
a Polydispersity index. bNormalized longitudinal relaxivity r1,
calculated from the measurement of water proton longitudinal
relaxation rate Robs1 (20 MHz, 25 °C).
cMembrane water permeability.
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Under the same conditions, JDG1G2(3,5) dendrimersomes
showed a reduced and time-decreasing retention capability,
while JDG0G1(3,5)-based vesicles displayed the highest stabi-
lity. To investigate in more detail the effects caused by serum
components on vesicular stability, additional release experi-
ments were performed for the two most stable dendrimer-
somes based on (3,5)-substituted JDs. Unlike the previous
experiments, the longitudinal water proton relaxation rate
Robs1 and the Gd
3+ content were determined on dialyzed
samples previously incubated in a given medium (buffer, HS
or HSA) for different time intervals up to 6 hours. In isotonic
buffer, no appreciable release was observed over 6 h (Fig. S4†).
In contrast, in HS some Gadoteridol was released already after
very short incubation times (Fig. 4). Payload releases of about
45% and 25% were detected after 1 h for dendrimersomes
based on JDG1G2(3,5) and JDG0G1(3,5), respectively. Finally,
the normalized r1p value calculated at each time point
remained constant and reproduced the expected values
reported in Table 1, to indicate that no significant structural/
dynamic variations occurred for the metal chelate entrapped
in the nanovesicles.
Because serum albumin is the most abundant plasma
protein,28 its interaction with JDG0G1(3,5)-based nanovesicles
was investigated. The results obtained (Fig. 5) paralleled the
data observed in HS.
PDI changes were observed after incubation with HS or HSA
(Fig. 6), suggesting that the interaction with plasmatic com-
ponents may somehow destabilize the membrane of the vesi-
cles.29 In accordance with the data on Gadoteridol release, the
PDI values of dendrimersome suspensions increased just after
incubation with HS/HSA.
The loss of dimensional uniformity appeared to be more
dramatic on JDG1G2(3,5)-based vesicles, which also displayed
a higher Gadoteridol release under the same incubation con-
ditions. We can tentatively hypothesize that a stronger affinity
of the higher generation dendrimer towards the serum pro-
teins might be responsible for the lower stability of the
JDG1G2(3,5)-based vesicles in these media.
Finally, JDG0G1(3,5)-based dendrimersomes presented a
capability of payload retention similar to that of the conven-
tional formulation of liposomes (Fig. 7). After incubation at
different temperatures (4 °C and 37 °C) or in the presence of
HSA, the gadolinium(III) content in the suspensions was
similar to the initial concentration of both dendrimersomes
Fig. 3 Stability and payload release in the presence of human serum.
(a) Water proton longitudinal relaxation rate values measured for
suspensions of dendrimersomes composed of different JDs incubated
for 1 h in human serum at 37 °C and successively dialyzed along con-
secutive time intervals (12 h each). (b) Concentration of Gd3+ in the den-
drimersome suspension before and after dialysis (6 cycles).
Fig. 4 In vitro stability of (3,5)JD-based dendrimersomes in human serum. (a) Water proton longitudinal relaxation rate of different suspensions of
dendrimersomes in human serum as a function of the incubation time at 37 °C. Robs1 was measured on the samples after dialysis. (b) Residual concen-
tration of Gd3+ in the sample, and (c) normalized longitudinal relaxivity at each time point.
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and liposomes. Nevertheless, as previously reported,26 for all
tested conditions the longitudinal relaxivity (r1p) resulted to be
higher for dendrimersomes due to the high water permeability
of their membrane.
2.4 Cytotoxicity and cell proliferation
The more stable JDG0G1(3,5)-based dendrimersomes were
further tested for their biocompatibility on two murine macro-
phage (RAW 264.7 and J774A.1) and one murine fibroblast
(Fig. 8, S5, and S6†) cell lines. Cell viability was tested using
Trypan Blue and resazurin–resorufin assays. Cells were incu-
bated with the dendrimersomes at different concentrations
ranging from 0.1 to 10 mg ml−1 of JDs. In the Trypan Blue
exclusion assay, both empty and Gadoteridol-containing
vesicles were tested and in both cases the cell viability was
found to be unaffected. Even longer incubation times (up to
48 hours) and the presence of highly concentrated dendrimer-
somes (10 mg ml−1) did not influence cell viability. Further-
more, no significant differences were observed between
vesicles encapsulating Gadoteridol or not, with cell viability
matching the controls in both cases. Resazurin–resorufin
assays provided additional confirmation of these results,
indicating that all tested cell lines retained active metabolism
after 1 h exposure to Gadoteridol-loaded dendrimersomes.
The proliferation rate of both cell lines was assessed after 1 h
incubation with highly concentrated suspensions of dendri-
mersomes (Fig. 9).
The nanovesicles did not affect cell proliferation, and no
differences in growth kinetics were noticed for any tested
material with respect to control incubation with PBS.
Similar data were also collected for JDG1G2(3,5)-based den-
drimersomes, with no significant effects on cell viability and
proliferation (Fig. S7–S10†).
2.5 Blood circulation lifetime
JDG0G1(3,5) dendrimersomes loaded with Gadoteridol were
i.v. injected into healthy BALB/c mice and the amount of
circulating gadolinium(III) was quantified by ICP-MS at
different time points (until 24 h post-injection, Fig. 10). The
in vivo results were compared to those obtained for conven-
tional liposomes prepared with a standard membrane
formulation (containing the same PEGylated component,
DSPE-PEG2000-COOH), and to those observed by injecting
an equivalent dose of free Gadoteridol. After the adminis-
Fig. 6 Changes in dimensional homogeneity. Percentage variation of the polydispersity index (PDI) of dendrimersomes as a function of incubation
times at 37 °C with (a) isotonic buffer, (b) human serum, and (c) human serum albumin.
Fig. 5 In vitro stability of (3,5)JD-based dendrimersomes in human serum albumin. (a) Water proton longitudinal relaxation rate of different suspen-
sions of dendrimersomes in human serum albumin (HSA, 50 mg ml−1) as a function of the incubation time at 37 °C. Robs1 was measured on the
samples after dialysis. (b) Residual concentration of Gd3+ in the sample, and (c) normalized longitudinal relaxivity at each time point.
Nanoscale Paper
This journal is © The Royal Society of Chemistry 2015 Nanoscale, 2015, 7, 12943–12954 | 12947
tration of dendrimersomes, the gadolinium(III) content in
mice blood progressively decreased, being completely elimi-
nated from circulation within 24 h. A blood lifetime of
70–80 min could be extrapolated by a simple visual inspection
of the data.
Liposomes showed a very similar trend. Interestingly, the
amount of Gd3+ measured few minutes after injection was ca.
25% lower than the injected dose for both the nanovesicular
systems, thus suggesting that the initial release of Gadoteridol
observed in vitro may also occur in vivo with a much faster
kinetics.
Nevertheless, the decrease in the plasmatic Gadoteridol
concentrationwas evenmore rapid, confirming that the inclusion
into both nano-sized carriers provides an advantageous clear-
ance delay for in vivo use. Furthermore, a different biodistribu-
tion profile between Gadoteridol-loaded vesicles and free
Gadoteridol was also proved by the tissue quantification of
GdIII at 24 h post-injection, revealing that dendrimersomes
and liposomes accumulate in liver and spleen, i.e. the macro-
phage-rich organs commonly responsible for the blood
removal of nanoparticles (Fig. S11, ESI†).
3. Discussion
Research on nanocarriers is rising exponentially as innovative
medical approaches require high specificity and efficiency in
local delivery of molecules employed for therapy or diagno-
sis.30 New nanoplatforms are continuously proposed in the
search for effective solutions to deliver a high molecular
payload to the biological target.31 As far as in vivo diagnostic or
theranostic imaging is concerned, nanomaterials are very
useful, especially in the MRI field,32,33 since the intrinsic low
sensitivity of the technique requires a high payload of efficient
contrast agent molecules to generate a locally detectable
signal. We have recently proposed the use of paramagnetic
nanovesicles formed by the self-assembling of Janus dendri-
mers as novel nanosized MRI contrast agents.26 As for other
nanovesicular systems,34 also in dendrimersomes the para-
magnetic contrast agent can be embedded in the membrane,
entrapped in the aqueous core, or covalently attached to the
membrane components giving rise to different relaxivity
enhancements depending on the location of the MRI probe in
the nanoparticle.26 We also found that the dendrimeric bilayer
is highly permeable to water,26 thus allowing us to obtain
higher relaxivities and improving the MRI detection of the
nanoparticles.
Although many of the recently proposed nanocarriers are
designed as ideal constructs for drug delivery and non-invasive
imaging, most of them failed when placed into complex bio-
logical systems.35,36 One of the most frequent drawbacks is
related to the loss of stability and uncontrolled release of
loaded molecules.37–39 Hence, this issue has to be carefully
considered before devising biological uses. In addition, since
in liposomes high water permeability is very often associated
with a poor stability of the nanovesicles and a limited reten-
tion of entrapped molecules, there is further interest to check
the behaviour of dendrimersomes.
As in most of the biomedical applications nanomaterials
are systemically administered, the first biological medium to
consider is blood.40,41 A good prediction of the in vivo stability
of nanoparticles can be obtained by studying the in vitro be-
haviour in plasma-mimicking fluids. Nano-objects encapsulat-
ing substances inside the internal compartments should be
carefully tested for their stability, since undesirable release
events have been already described for standard liposome for-
mulations after their interaction with different plasmatic
components.40–45 Interestingly, in many cases the release
appears to follow a two-phase time dependence, with a rapid
release in the early phase after injection, followed by a slower
phase, likely associated with the biodistribution/excretion of
the nanoparticles.46–50 Despite the lack of a detailed description
of the mechanisms driving this phenomenon, a number of
hypotheses have been proposed, including lipoprotein-
mediated lipid transfer and direct interaction with albumin or
lipoproteins.41,42,49
Although detailed studies about the structural stability of
dendrimersomes have already been reported,16–20 these did
not consider specifically and thoroughly the role of biological
Fig. 7 Stability and payload release of JDG0G1(3,5)-based dendrimer-
somes and standard liposomes. (a) Concentration of Gd3+ measured for
suspensions of JDG0G1(3,5)-based dendrimersomes (Gd-DS) and stan-
dard liposomes (Gd-Lipo) immediately after preparation (t = 0), after
incubation for 1 h at 4 °C, at 37 °C and at 37 °C in the presence of
human serum albumin. (b) Normalized longitudinal relaxivity (r1p) calcu-
lated for the vesicular suspensions.
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variables. For this reason, we considered it important to
devote efforts to assess the ability of Gadoteridol-loaded den-
drimersomes to retain their payload in a blood-like
environment.
Peterca et al. have recently demonstrated the presence of a
direct correlation between the molecular structure of the den-
drimer and the morphology of the supramolecular assem-
blies.17 Specifically, the geometric pattern of the hydrophobic
Fig. 8 Effects of JDG0G1(3,5)-based dendrimersomes on cell viability. Cell viability estimated by the Trypan Blue assay on (a) RAW 264.7 cells, (b)
J774A.1 cells and (c) NIH/3T3 cells after incubation along different incubation times with PBS or JDG0G1(3,5)-based vesicles at a high concentration
(10 mg ml−1), encapsulating Gadoteridol or not (Gd-DS and DS respectively; (d) cell viability estimated by the resazurin/resorufin assay after 1 h incu-
bation with JDG0G1(3,5)-based vesicles at different concentrations (0.1/1/10 mg ml−1).
Fig. 9 Effects of JDG0G1(3,5)-based dendrimersomes on cell proliferation. The proliferation rate of (a) RAW 264.7 cells, (b) J774A.1 cells and (c)
NIH/3T3 cells after 1 h incubation with PBS or JDG0G1(3,5)-based dendrimersomes (10 mg ml−1 of JD), loaded with Gadoteridol or not (Gd-DS and
DS, respectively). Nt and N0 represent the number of cells at each time point and the number of cells present at the beginning of the experiment
respectively.
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branching moiety in JDs can represent a key factor for the
layer thickness inside lamellar phases in bulk and in the ves-
icular wall. Vesicles self-assembled from JDs with 3,5-bis(do-
decyloxy)benzene hydrophobic groups were reported to be
characterized by thinner walls, larger dimensions, and higher
resistance to mechanical stress with respect to the 3,4-functio-
nalized isomers. The explanation is to be found in the thicker
interdigitation pattern arising from the more separated alkyl
chains in the former JDs. Since wall packing density and vesi-
cular architecture are also responsible for the mechanical pro-
perties of the particles, it is likely that dendrimersome stability
and the release of their content are related to this phenom-
enon. Larger dendrimersomes with thinner membranes were
described as tougher and generally more stable under storage
conditions.17
Consistently, in the present study, dendrimersomes based
on JDs with the 3,5-pattern (JDG0G1(3,5) and JDG1G2(3,5)) dis-
played a greater ability to retain the transported material than
vesicles made of the (3,4) analogues even in isotonic buffer at
4 °C. Interestingly, the stability in HS and HSA of the dendri-
mersomes composed of JDG0G1(3,5) was higher than that of
the vesicles previously reported, made of higher generation
JDs. As already observed in several cases, the release of the
payload is stimulated by the interaction of the particles with
plasma proteins,48–50 as demonstrated by an increase in the
polydispersity of the nanosystems that shows a good corre-
lation with the release data. However, after a first release
“burst” (about 25% after 1 h), the nanovesicles displayed an
excellent stability and the amount of encapsulated Gadoteridol
did not change within 2 days of incubation in HS at 37 °C.
Another relevant finding of this work is the high biocom-
patibility displayed by JDG0G1(3,5)-based dendrimersomes.
In fact, the particles (both empty and loaded with Gadoteridol)
did not produce any negative effect on cell viability and the
proliferation rate, which augurs well for their use in
biomedicine.
Moreover, for the first time dendrimersomes were tested on
animals with the primary aim of determining their blood cir-
culation lifetime, which is one of the most important pro-
perties for assessing the in vivo potential of a nanoparticle.
Given the difficulty of comparing biodistribution data in vivo
because of the high number of variables involved, we decided
to compare the blood kinetics of JDG0G1(3,5)-based nanovesi-
cles with that of standard liposomes of a similar size
(146.4 nm) on the same animal model (BALB/C healthy male
mice with the same age and weight), using an identical analyti-
cal technique (ICP-MS) for the determination of the blood con-
centration of Gd3+. The data reported in Fig. 10 indicated that
the two nanosystems display very similar profiles. According to
non-parametric independent statistic tests such as Kolmo-
gorov–Smirnov and Mann–Whitney analyses, the difference
between the two samples did not result to be statistically
significant.
A blood lifetime of ca. 70–80 min can be extrapolated for
both nanosystems. However, it is worth noting that the
amount of Gd3+ found in the blood five minutes after injection
of the nanovesicles was ca. 25–30% lower than the total
amount injected. This fraction closely corresponds to the
amount of Gadoteridol released from the dendrimersomes in
vitro after incubation for 1 h in the presence of HSA or HS
(Fig. 4 and 5). Likely, the mechanism(s) responsible for the
“burst” release of Gadoteridol occurred in vivo on a much
shorter timescale.
Interestingly, the confirmation of the initial fast release of
Gadoteridol was achieved by measuring the blood kinetics of
free Gadoteridol (Fig. 10). In fact, the reduction of GdIII blood
concentration few minutes after injecting the free complex was
very similar to what was determined for the nanovesicular
form of the agent. Then, for longer times, the free complex
was cleared faster, thus highlighting the prolonged circulation
times of the Gd-loaded nanoparticles.
Considering such a very fast initial release, the actual blood
lifetime of the nanoparticles related to their tissue/organ
accumulation will be longer, around 90–120 min. This range
of values has been already reported for stealth liposomes in
healthy animals.51,52
Very importantly, during the in vivo experiments neither
acute episodes of toxicity nor other side effects on general
health conditions of animals were noticed, thereby indicating
that dendrimersomes could effectively be employed in biologi-
cal applications.
4. Experimental
4.1 Chemicals
The phospholipid 1,2-distearoyl-sn-glycero-3 phosphoethanol-
amine-N-[carboxy(polyethylene glycol)-2000] ammonium salt
Fig. 10 Blood circulation lifetime. Kinetics of gadolinium concentration
in blood normalized to the injected dose ([Gd]t/[Gd]0) into healthy
BALB/c mice after systemic injection of Gadoteridol (white circles),
JDG0G1(3,5) dendrimersomes (Gd-DS, white squares, error bars in grey)
and control liposomes (Gd-Lipo, black squares) both loaded with Gado-
teridol. All animals received equivalent Gadoteridol doses (0.16 mmol
per kg bw).
Paper Nanoscale
12950 | Nanoscale, 2015, 7, 12943–12954 This journal is © The Royal Society of Chemistry 2015
(DSPE-PEG2000-COOH) and 1,2-dipalmitoyl-sn-glycero-3-phos-
phocholine (DPPC) were purchased from Avanti Polar Lipids
Inc. (Alabaster, AL, USA). Gadoteridol (Gd-HPDO3A, marketed
as ProHance™) was kindly provided by Bracco Imaging S.p.A.
(Colleretto Giacosa, Torino, Italy). All other chemicals and
reagents were purchased from Sigma-Aldrich (St Louis, USA),
and used as received except where noted otherwise.
4.2 Animals
Healthy male BALB/c mice involved in the study were obtained
from Charles River Laboratories (Calco (LC), Italy) and main-
tained under standard housing conditions, with water and
standard rodent chow ad libitum and a 12 h light/dark cycle.
Animal manipulation and all experimental procedures were
performed in accordance with the European Community
guidelines and approved by the Ethical Committee of Univer-
sity of Torino.
4.3 Synthesis of Janus dendrimers
The synthesis and characterization of (3,4)12G1-PE-BMPA-G2-
(OH)8 and (3,5)12G1-PE-BMPA-G2-(OH)8 Janus dendrimers
(JDG1G2(3,4) and JDG1G2(3,5) in Fig. 1) were performed as
described elsewhere.16,17,53 The synthesis of JDG0G1(3,4) and
JDG0G1(3,5) is described in detail in the ESI.† Briefly, the
new amphiphiles were obtained by linking to an ethylene
glycol spacer one hydrophobic block (3,4 or 3,5 bis-dodecyl
substituted benzoyl ether) and a generation 1 BPMA-based
hydrophilic moiety (BPMA: 2,2-bis(hydroxymethyl)propanoic
acid).
4.4 Dendrimersome preparation
Dendrimersomes were prepared by the thin film hydration
method.54 Briefly, appropriate amounts of JDs and
DSPE-PEG2000-COOH (a molar ratio of 95 : 5) were dissolved
in chloroform. The organic solvent was slowly removed with a
rotary evaporator, letting the amphiphilic components be dis-
tributed in a thin homogeneous film. After two hours under
vacuum, the films were hydrated at 50 °C with an isotonic
buffered HEPES solution (pH 7.4) containing 250 mM Gado-
teridol. The samples were then extruded through polycarbo-
nate filters (Lipex Extruder, Northern Lipids Inc.) with pore
diameters decreasing from 1 μm to 200 nm. After the extrusion
process, the final suspensions underwent an exhaustive dialy-
sis process against isotonic buffer at 4 °C to remove the non-
encapsulated agent. DLS measurements allowed the deter-
mination of the mean hydrodynamic diameter of the vesicles
and their PDI. The value of the membrane water permeability
of the dendrimersomes was determined relaxometrically.55
Further details about the vesicles’ preparation and characteri-
zation are available in the ESI.†
4.5 Cryo-TEM
Vitrified specimens were prepared by placing 3 μl of a sample
on a Quantifoil® 1.2/1.3 TEM grid. Each sample was blotted to
a thin film and immediately plunged into liquid ethane in the
Leica EM CPC cryoworkstation. The grids were transferred to a
626 Gatan cryoholder and maintained at −179 °C during
imaging. The grids were studied using a JEOL 2011 trans-
mission electron microscope operating at an accelerating
voltage of 200 kV. Micrographs were recorded using a Gatan
Ultrascan cooled charge-coupled device (CCD) camera under
low electron dose conditions to minimize electron bean
radiation.
4.6 In vitro stability
In order to test the stability within a biological environment,
dendrimersomes loaded with Gadoteridol were incubated with
isotonic solutions of plasma components at pH 7.4 and 37 °C.
The stability was evaluated by measuring the amount of
released Gadoteridol by relaxometry (water proton longitudinal
relaxation rate Robs1 measurements). Vesicular suspensions
(10 mg ml−1 of amphiphilic material) were diluted (ratio 1 : 2)
with human serum albumin (50 mg ml−1) or human serum
(SERO, Billingstad, Norway) and kept at 37 °C for the required
incubation time. Control tests were carried out by incubating
the vesicles in isotonic HEPES buffer at 4 °C or 37 °C. The MRI
agent released from the vesicles during incubation was
removed by dialysis at 4 °C (6 h, receiving phase/donor phase
volume >1500).
In a first set of experiments, dendrimersomes were incu-
bated for 1 h. Then, a prolonged dialysis was carried out at
4 °C with recursive buffer renewals to completely wash out the
non-encapsulated agent. The amount of gadolinium in the
samples was assessed before and after the dialysis, while the
observed water proton longitudinal relaxation rate Robs1 was
measured at each buffer renewal.
In a second set of experiments, an aliquot of the incubated
sample was taken at each time point and subjected to a 6 h
dialysis cycle at 4 °C. After that, the gadolinium content in the
suspension and Robs1 of the sample were measured.
In order to evaluate size and/or polydispersity changes
occurring in the dendrimersomes, some aliquots of the
samples incubated at 37 °C with buffer, HSA or HS, were col-
lected to be tested by DLS. Since DLS measurements can be
severely affected by the presence of proteins, samples incu-
bated with HSA or HS were dialyzed using membranes with a
100 kDa molecular weight cut-off, which permit the transit of
proteins, but prevent the passage of the much bigger
nanoparticles.
In a third set of experiments, the stability, the payload
release and the contrast properties of dendrimersomes were
compared to those observed for liposomes. For control lipo-
somes, a standard membrane formulation was chosen (DPPC
and DSPE-PEG2000-COOH in molar ratio 19 : 1). The normal-
ized longitudinal relaxivity (r1p) and the gadolinium(III)
content of vesicular suspensions were calculated (as explained
in the following paragraphs) on the samples immediately after
preparation, or after 1 h incubation at 4 °C, at 37 °C and at
37 °C in the presence of HSA.
See the ESI† for additional information about the stability
experiments performed.
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4.7 1H NMR relaxation measurements
The observed water proton longitudinal relaxation rate (Robs1 )
values were measured on a Stelar SpinMaster Spectrometer
(Stelar Snc, Mede (PV), Italy) operating at 20 MHz by using the
standard inversion recovery pulse sequence with 4 scans for
each acquired data point. A precise control of the temperature
was operated during the measurements by means of a Stelar
VTC-91 airflow heater equipped with a calibrated copper con-
stantan thermocouple (uncertainty of ±0.1 °C). Furthermore,
the actual temperature inside the probe head was additionally
monitored by a Fluke 52 k/j digital thermometer (Fluke,
Zürich, Switzerland). The concentration of Gd3+ in the samples
was determined by a relaxometric procedure (at 20 MHz) after
mineralization. Briefly, the samples were diluted 1 : 2 into con-
centrated HCl (37%) and stored overnight at high temperature
(120 °C) in a sealed glass ampoule, to effectively displace
the metal ions from the complexes and to obtain a solution
containing free Gd3+ in the form of an aqua-ion. The
Robs1 measurement (at 25 °C) allowed for the accurate esti-
mation of the Gd3+ concentration through a calibration line
obtained by using standard solutions of GdCl3.
56
4.8 Cells
All cell lines were obtained from American Type Culture Col-
lection (ATCC, Manassas, VA, USA) and resulted negative for
the mycoplasma test (MycoAlert™ Mycoplasma Detection Kit,
Lonza Sales AG, Verviers, Belgium). Murine macrophages
(J774A.1 and RAW 264.7 cell lines) and fibroblasts (NIH/3T3
cell line) were cultured as monolayers at 37 °C under a 5%
CO2-containing humidified atmosphere in Dulbecco’s modi-
fied Eagle’s medium (DMEM). The medium was supplemented
with 10% (v/v) of heat-inactivated fetal bovine serum, 2 mM of
glutamine, 100 U ml−1 of penicillin and 100 μg ml−1 of
streptomycin.
When cells reached confluence, the detachment was accom-
plished by mechanical removal by means of a scraper (macro-
phages) or by trypsin addition (fibroblasts). All cells employed
for cellular tests were at passages included between 3 and
7. Culture medium, fetal bovine serum, penicillin–streptomy-
cin mixture and trypsin were all purchased from Lonza (Lonza
Sales AG, Verviers, Belgium).
4.9 Cell viability and proliferation
To assess the cellular viability after incubation with the dendri-
mersomes, 5 × 104 RAW 264.7, J774A.1 or NIH/3T3 cells were
plated in culture dishes. After 24 h, cells were added with den-
drimersomes (previously diluted into culture medium and fil-
tered using sterile 0.2 μm sized filters) at different incubation
times (up to 2 days), and particle concentrations (0.1, 1, and
10 mg ml−1 of JDs). Viable cells were counted by using a
Trypan Blue exclusion assay: a 0.4% solution of Trypan Blue in
phosphate buffered saline (pH 7.2–7.3; 1 : 1 v/v) was added to
harvested cells before counting. Cells added with neat-buffered
solution were used as control. Each incubation experiment was
replicated eight times, and the reported cell viability percen-
tage value represents the average ratio between the number of
vital cells and the total number of cells counted in each experi-
ment (i.e. Nv/Nt × 100).
In order to confirm the results obtained by the Trypan Blue
exclusion assay, dendrimersome cytotoxicity was further inves-
tigated by means of a fluorimetric cell viability assay, based on
the cell metabolic activity (CellTiter-Blue® Cell Viability Assay,
Promega, Madison, USA). The CellTiter-Blue® reagent contains
the indicator dye resazurin that is reduced to highly fluo-
rescent resorufin by viable cells retaining metabolic capacities,
so that the fluorescence signal generated from the assay is pro-
portional to the number of living cells in the sample. Briefly,
J774A.1, RAW 264.7 and NIH/3T3 cells were plated in a 96-well
multiwall plate at concentrations of 1.0 × 104, 1.5 × 104 and
1.0 × 104 cells per well, respectively. After 24 h, cells were
exposed to a fresh medium containing Gadoteridol-loaded den-
drimersomes. After incubation for 1 h, the incubation medium
was removed and wells were washed three times with sterile
PBS. Then, the CellTiter-Blue® reagent was added following
the manufacturer’s instructions (20 μl of reagent diluted 1 : 5
into culture medium for each well). After 4 h, supernatants
were collected and placed in a black 96-well multiwell plate for
fluorescence detection (excitation wavelength 530–560 nm,
emission wavelength 590 nm). For each condition, six indepen-
dent experiments were performed in triplicate and fluo-
rescence measurements were repeated three times. The results
are expressed as the mean ± SD of the percentage of viable
cells, normalized with respect to control samples obtained by
incubating cells with PBS-containing medium.
Proliferation tests were performed by incubating cells with
dendrimersomes (10 mg ml−1 of JDs in culture medium) for
1 h. Then, the cells were seeded into round plastic dishes and
maintained in a fresh culture medium for different time
ranges (up to 7 days). Cells were then detached, collected, and
counted by the Trypan Blue assay at each time point. Each
experiment was replicated five times. Cell proliferation was
expressed as the ratio between the number of viable cells at
each time point and the number of cells present at the begin-
ning of the experiment (i.e. Nt/N0).
4.10 In vivo stability
In vivo stability was investigated by injecting dendrimersomes
via the tail vein into healthy male BALB/c mice (8 weeks,
24–25 g). Each experiment was performed at least on three
different animals. Gadoteridol-loaded dendrimersomes and
liposomes (40 mg ml−1 of phospholipids) were relaxometrically
analysed for their Gd3+ content and animals were administered
to receive the same dose of GdIII (0.16 mmol kg−1). A standard
membrane formulation was chosen for liposomes consisting
of DPPC and DSPE-PEG2000-COOH in a molar ratio 19 : 1. The
results obtained for the two nanosystems were further com-
pared to the in vivo kinetics of the free Gadoteridol at an equi-
valent dose. After injection, blood was sampled at different
times up to 24 h, to measure the amount of circulating GdIII.
Animals were then sacrificed to obtain the organs (liver,
spleen, kidneys, muscle, heart, lung) and to quantify the tissue
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metal concentration (see the ESI† for further details). The
metal quantification was performed by ICP-MS measurement,
after all biological specimens were completely digested into
acid. Briefly, the collected blood was immediately added to
heparin (20 μL, Sigma-Aldrich, St Louis, USA) and its volume
was accurately measured. Each sample was treated with con-
centrated HNO3 (70%) and digested by microwave heating
(Milestone MicroSYNTH, Microwave Labstation equipped with
an optical fiber temperature control and HPR-1000/6M six
position high-pressure reactor, Bergamo, Italy). After digestion,
the remaining material was diluted in ultrapure water (final
volume of 3 mL) and further filtered with 0.2 μm filters.
Finally, samples were analysed by ICP-MS (Thermo Scientific
ELEMENT 2 ICP-MS-Finnigan, Rodano, Milano, Italy) to
measure the Gd3+ content. These values were finally reported
as metal concentration values in blood by calculating the Total
Blood Volume (TBV) for each animal from the average value
reported for mice (79 ml kg−1).57
5. Conclusions
In the present work, we report on the synthesis of new low-
generation Janus dendrimers through a simplified synthetic
pathway. In aqueous media, these amphiphiles spontaneously
form nanovesicular dendrimersomes with size and PDI similar
to higher generation JDs. The nanovesicles were loaded with
the clinically approved MRI contrast agent Gadoteridol and 1H
NMR relaxometric measurements confirmed the high water
permeability of the membrane of the new dendrimersomes, in
analogy to their higher generation analogues. The payload
stability of the nanovesicles was tested for the first time in
human serum. The data indicate that one of the newly syn-
thesized JDs (JDG0G1(3,5)) form dendrimersomes with a
greater stability than its higher generation precursor, as only a
small percentage (ca. 25%) of Gadoteridol was released in the
presence of serum.
In addition, these novel vesicles displayed a very high bio-
compatibility and no negative effects on cell viability and the
proliferation rate were observed on fibroblasts and on two
populations of murine macrophages. Furthermore, PEGylated
dendrimersomes were seen to remain in blood vessels and to
circulate for time periods comparable to those of conventional
liposomes with a similar size that represent a well established
tool for several biomedical applications.
Overall, these promising results suggest that JDG0G1(3,5)-
based dendrimersomes are good candidates for the develop-
ment of effective nanosystems for medical bioimaging. Future
work will be directed to test the diagnostic/therapeutic/thera-
nostic potential of this new class of soft nanoparticles at the
preclinical level.
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